Skip to main content

Table 5 SVR12 values for observational study regimens with and without RBV in patients who were (i) cirrhotic or non-cirrhotic a, (ii) treatment-experienced or -naïve, or (iii) HIV-positive or -negative

From: Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review

Regimen

SVR12% [95% CI]

Cirrhotic

Non-cirrhotic

Treatment-experienced

Treatment-naïve

HIV-positive

HIV-negative

DCV + SOF containing regimens

 DCV + SOF

+RBV

77.3

[70.9, 83.2]

n = 186

83.3

[41.4, 100.0]

n = 6

74.4

[66.7, 81.6]

n = 139

100.0

[86.1, 100.0]

n = 12

100.0

[73.9, 100.0]

n = 6

NR

−RBV

85.4

[79.7, 90.3]

n = 215

98.1 [92.2, 100.0]

n = 54

81.1

[65.3, 93.5]

n = 35

90.5

[73.4, 99.8]

n = 21

97.7

[82.5, 100.0]

n = 20

NR

±RBV

84.8

[33.3, 100.0]b

n = 5

NR

100.0

[73.2, 100.0]b

n = 6

NR

NR

90.9

[65.0, 100.0]b

n = 11

LDV containing regimens

 LDV + SOF

+RBV

64.9

[52.0, 76.8]

n = 57

NR

70.9

[54.0, 86.0]

n = 63

NR

NR

NR

−RBV

40.0

[1.8, 86.2]

n = 5

NR

28.6

[1.0, 68.2]

n = 7

NR

NR

NR

SOF containing regimens

 SOF

+RBV

49.3

[40.8, 57.7]

n = 144

81.9

[74.7, 88.2]

n = 138

60.5

[50.2, 70.4]

n = 105

74.3

[66.4, 81.5]

n = 144

100.0

[30.3, 100.0]

n = 2

NR

−RBV

NR

NR

NR

NR

NR

NR

 SOF ± Peg-IFN

+RBV

90.9

[74.5, 99.8]

n = 22

NR

91.7

[67.6, 100.0]

n = 12

NR

NR

NR

−RBV

NR

NR

NR

NR

NR

NR

Peg-IFN containing regimens

 Peg-IFN

+RBV

63.9

[60.0, 67.7]

n = 713

77.8

[74.8, 80.7]

n = 845

49.4

[43.1, 55.7]

n = 257

63.3

[62.6, 64.1]

n = 16,031

66.4

[63.1, 69.6]

n = 874

63.7

[62.8, 64.6]

n = 11,995

−RBV

NR

NR

NR

NR

NR

NR

 Peg-IFN + SOF

+RBV

100.0

[30.3, 100.0]

n = 2

NR

NR

NR

NR

NR

−RBV

NR

NR

NR

NR

NR

NR

  1. DCV daclatasvir, IFN interferon, LDV ledipasvir, NR not reported, RBV ribavirin, r ritonavir, SOF sofosbuvir, SVR12 sustained virological response at 12 weeks
  2. aIn this analysis, cohorts were considered non-cirrhotic if 0% of patients were cirrhotic
  3. bData from study(s) in which stratification by RBV use was not recorded